-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin
.
In recent years, the incidence of this disease has increased significantly due to the increase in the average age of the population and the use of immunosuppressive treatments
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin
The study retrospectively included 143 patients, 74 men and 69 women
.
The median age at diagnosis was 71 years
The study retrospectively included 143 patients, 74 men and 69 women
Extensive resection (WE) is the most common treatment for the primary lesion (101 cases, 71%)
The median follow-up time of 128 patients with stage I-III was 31 months (IQR 15-62)
OS and disease-specific survival
OS and disease-specific survivalUnivariate analysis found that poor OS was associated with increased age (HR=1.
03, 95% CI 1.
00-1.
06) and a higher Charlson comorbidity index (HR=1.
16, 95% CI 1.
01-1.
33)
.
Poor disease-specific survival is related to the presence of autoimmune diseases (HR=2.
Univariate analysis found that poor OS was associated with increased age (HR=1.
Univariate analysis of OS and disease-specific survival
Univariate analysis of OS and disease-specific survivalAt the time of data analysis, 43 out of 102 patients with stage I-III primary disease relapsed (43%)
.
There were 11 cases of local recurrence, 15 cases of lymph node metastasis, and 13 cases of distant metastasis
At the time of data analysis, 43 out of 102 patients with stage I-III primary disease relapsed (43%)
Recurrence-free survival
Relapse- free survivalPoor recurrence-free survival is related to the application of immunomodulatory drugs (HR=2.
51, 95% CI 1.
36-4.
57; p = 0.
003) and radiotherapy (HR=2.
74, 95% CI 1.
50-5.
03; p = 0.
001)
.
In patients with stage I-III who received extensive resection of the primary tumor and received SNB treatment, the recurrence-free survival was not related to SNB positive (HR=1.
Poor recurrence-free survival is related to the application of immunomodulatory drugs (HR=2.
51, 95% CI 1.
36-4.
57; p = 0.
003) and radiotherapy (HR=2.
74, 95% CI 1.
50-5.
03; p = 0.
001)
.
In patients with stage I-III who received extensive resection of the primary tumor and received SNB treatment, the recurrence-free survival was not related to SNB positive (HR=1.
00, 95% CI 0.
38-2.
65; p = 0.
99)
.
Compared with patients with CLND≤2 positive lymph nodes, patients with CLND≥3 positive lymph nodes had no significant difference in recurrence-free survival (HR=2.
05, 95% CI 0.
85-4.
94; p = 0.
11)
.
Univariate analysis of relapse-free survival
Univariate analysis of recurrence- free survival Univariate analysis of recurrence-free survival
In summary, the study found that autoimmune and tumor comorbidities are common in MCC patients, and the use of immunomodulatory drugs is also common
.
.
The study found that autoimmune and tumor comorbidities are common in MCC patients, and the use of immunomodulatory drugs is also common
.
The study found that autoimmune and tumor comorbidities are common in MCC patients, and the use of immunomodulatory drugs is also common
.
Original source:
Original source:Rastrelli M, Del Fiore P, Russo I, et al (2021) Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143).
Front.
Oncol.
11:737842 .
doi: 10.
3389/fonc.
2021.
737842
Front.
Oncol.
11:737842 .
doi: 10.
3389/fonc.
2021.
737842 leave a message here